ArticleLipids in health and disease2023
Comparison of the diagnostic performance of twelve noninvasive scores of metabolic dysfunction-associated fatty liver disease.
Article in Lipids in health and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Pooled it
- Comparative Diagnostic Performance of Metabolic Scoring Indices for Ultrasonographic Hepatic Steatosis: Development and Validation of a Novel Composite Score in 1204 Consecutive Patients.Journal of clinical medicine · 2026Article
- Article
- Simplicity meets accuracy: TyG-Waist as a practical alternative to CVAI for type 2 diabetes prediction in high-risk Chinese adults.BMC endocrine disorders · 2026Article
- The relationship between triglyceride-glucose index, triglyceride-glucose-body mass index, and the severity of hepatic steatosis and liver fibrosis in patients with MASLD: a cross-sectional study.Frontiers in nutrition · 2026Article
- Comparative performance of multiple novel obesity indices for MAFLD screening in Chinese children: the body roundness index as a practical predictor.Frontiers in medicine · 2026Article
- Incorporating Insulin Resistance Biomarkers into Machine Learning Models Enhances Diagnostic Accuracy for Metabolic Dysfunction-Associated Steatotic Liver Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Body Mass Index Outperforms Triglyceride-Glucose Index in Predicting MAFLD in Type 2 Diabetes: A Cross-Sectional Mediation and Interaction Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Personalized MASLD and liver fibrosis risk assessment for adults: glycemic status determines optimal choice of non-invasive indices.Diabetology & metabolic syndrome · 2025Article
- Article
- Association between dietary quality index - international (DQI-I) and fatty liver indices: results from the Ravansar non-communicable disease (RaNCD) cohort study.Scientific reports · 2025Article
- Development and validation of an online nomogram for screening metabolic-associated fatty liver disease in obese children.Italian journal of pediatrics · 2025Article
- Comparative analysis of insulin resistance indicators in predicting reversion from prediabetes to normoglycemia.Diabetology & metabolic syndrome · 2025Article
- Comparison of Triglyceride-Glucose Index Indices and Fatty Liver Index in Predicting Metabolic Dysfunction-Associated Fatty Liver Disease: A Cross-Sectional Study Conducted in Vietnam.Life (Basel, Switzerland) · 2025Article
- Analysis of risk factors associated with metabolic-associated fatty liver disease from Suzhong Region, China: a cross-sectional study.BMJ open · 2025Article
- Optimal obesity and lipid-related predictors of diabetes mellitus in middle-aged and elderly patients with liver disease in China: a CHARLS cross-sectional study.Diabetology international · 2025Article
- Decoding the potential association of liver steatosis with female infertility: an analysis from NHANES 2013-2018.BMC public health · 2025Article
- Relationship between triglyceride and glucose related indexes and MAFLD in rural populations of northwest China.Scientific reports · 2025Article
- Identification of pediatric MASLD using insulin resistance indices.JHEP reports : innovation in hepatology · 2025Article
- The association between estimated glucose disposal rate and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in US adults.BMC endocrine disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe absence of distinct symptoms in the majority of individuals with metabolic dysfunction-associated fatty liver disease (MAFLD) poses challenges in identifying those at high risk, so we need simple, efficient and cost-effective noninvasive scores to aid healthcare professionals in patient identification. While most noninvasive scores were developed for the diagnosis of nonalcoholic fatty liver disease (NAFLD), consequently, the objective of this study was to systematically assess the diagnostic ability of 12 noninvasive scores (METS-IR/TyG/TyG-WC/TyG-BMI/TyG-WtHR/VAI/HSI/FLI/ZJU/FSI/K-NAFLD) for MAFLD.
methodsThe study recruited eligible participants from two sources: the National Health and Nutrition Examination Survey (NHANES) 2017-2020.3 cycle and the database of the West China Hospital Health Management Center. The performance of the model was assessed using various metrics, including area under the receiver operating characteristic curve (AUC), net reclassification index (NRI), integrated discrimination improvement (IDI), decision curve analysis (DCA), and subgroup analysis.
resultsA total of 7398 participants from the NHANES cohort and 4880 patients from the Western China cohort were included. TyG-WC had the best predictive power for MAFLD risk in the NHANES cohort (AUC 0.863, 95% CI 0.855-0.871), while TyG-BMI had the best predictive ability in the Western China cohort (AUC 0.903, 95% CI 0.895-0.911), outperforming other models, and in terms of IDI, NRI, DCA, and subgroup analysis combined, TyG-WC remained superior in the NAHANES cohort and TyG-BMI in the Western China cohort.
conclusionsTyG-BMI demonstrated satisfactory diagnostic efficacy in identifying individuals at a heightened risk of MAFLD in Western China. Conversely, TyG-WC exhibited the best diagnostic performance for MAFLD risk recognition in the United States population. These findings suggest the necessity of selecting the most suitable predictive models based on regional and ethnic variations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.